FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
netruction 1/h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average	burden						
hours per response	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Mottola Frank					SU	2. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS, INC. [SUPN]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify				
(Last) (First) (Middle) C/O SUPERNUS PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/22/2023								Sr VP, Quality, GMP Oper. & IT					
9715 KEY WEST AVENUE						4. If Amendment, Date of Original Filed (Month/Day/Year) 02/24/2023								i. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person				
(Street)	ILLE M	MD 20850				Form filed by More than One Reporting Person											- 1	
(City) (State) (Zip)				Rı	Rule 10b5-1(c) Transaction Indication													
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tabl	e I - No	n-Deriv	ative	Sec	uritie	es Ac	quired,	Dis	posed	of, or Be	eneficia	lly Owne	d			
Date			2. Trans Date (Month/I	Day/Year) E		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr. 5)		rities Acquired (A) or ed Of (D) (Instr. 3, 4 a		Benefic	es For ially (D) Following (I) (rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) oi (D)	Price	Transac (Instr. 3	tion(s)			(50.1 4)	
Common Stock			02/22	/2023				A		750	A	\$0	9,5	517(1)		D		
Common	Stock			02/22	2/2023				F		289(2	2) D	\$38.5	57 9,	228		D	
		Т										, or Ben		y Owned				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transactio Code (Insti		on of		6. Date Exercisabl Expiration Date (Month/Day/Year)		:	7. Title an Amount o Securities Underlyin Derivative (Instr. 3 an	f s g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares					
Restricted Stock Units	(3)	02/22/2023			D			750	(4)		(4)	Common Stock	750	\$0	2,250		D	

Explanation of Responses:

- $1. \ Includes \ an \ aggregate \ of \ 576 \ shares \ acquired \ by \ the \ Reporting \ Person \ through \ the \ Issuer's \ Employee \ Stock \ Purchase \ Plan.$
- 2. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
- 3. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- 4. These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023.

/s/ Timothy C. Dec, as attorney-in-fact

04/12/2023

** Signature of Reporting Person

Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.